NCIt definition : A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody directed against
the tumor-associated antigen (TAA) claudin18.2 (CLDN18.2; A2 isoform of claudin-18)
and the human T-cell surface antigen CD3, with potential immunostimulatory and antineoplastic
activities. Upon administration, gresonitamab simultaneously binds to both CD3-expressing
T-cells and CLDN18.2-expressing cancer cells, thereby crosslinking CLDN18.2-expressing
tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and
proliferation of T-cells and causes CTL-mediated cell lysis of CLDN18.2-expressing
tumor cells. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18,
is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly
confined to short-lived differentiated epithelial cells of the gastric mucosa.;
UNII : 0SIB91V6TP;
CAS number : 2413817-97-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2413817-97-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)